AstraZeneca at ObesityWeek 2026
Nov 14–17, 2026 National Harbor, MD ~4.4k attendees Website
AstraZeneca brings 1 presentation to ObesityWeek 2026 in National Harbor, and exhibits at Booth 301. Its program centres on AZD9550, a dual GLP-1 and glucagon receptor agonist, in fatty liver disease. In mice on a MASH diet, the drug improves liver fat even in animals lacking the GLP-1 receptor.
| Organization | ObesityWeek 2026 Attendance |
|---|---|
AstraZeneca Cambridge, UK | |
Its cardiovascular, renal and metabolism unit develops medicines that slow disease and protect the heart, kidneys, liver and pancreas. | Booth Exhibiting at Booth 301 Sat, Nov 147pm–9:30pmSun, Nov 159:30am–4pmMon, Nov 169:30am–4pm Poster Sat Nov 14 7:30pm–8:30pm AZD9550, a Dual GLP-1R/GCGR Agonist, Improves Hepatic Steatosis in Wild-Type and GLP-1R Knock-Out Mice on a MASH Diet Chronic disease and obesity complicationsMetabolism and integrative physiology |
Find decision makers at AstraZeneca
Tell us what you sell and we’ll find the people at AstraZeneca most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by The Obesity Society (TOS), ObesityWeek® or the American Society for Metabolic and Bariatric Surgery (ASMBS). Submit a correction